Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Leukemia » Leukemia, Myeloid » Leukemia, Myelomonocytic, Juvenile
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Bone Marrow Diseases » Myelodysplastic-Myeloproliferative Diseases » Leukemia, Myelomonocytic, Juvenile
Description
A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder. MeSH
Hierarchy View
Phase 4 Indicated Drugs (2)
Other Experimental Indicated Drugs (2)
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (11)
Organization Involved with Phase 2 Indications (92)
Arbeitsgemeinschaft medikamentoese Tumortherapie
Case Western Reserve University
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
City of Hope National Medical Center
Groupe Francophone des Myelodysplasies
National Heart, Lung, and Blood Institute (NHLBI)
Royal Marsden Hospital NHS Trust
service Hématologie Séniors Hôpital Saint Louis
State University of New York, Buffalo
Technical University of Denmark
University of California, Irvine
Organization Involved with Phase 1 Indications (24)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.